RxDoctor Payments Data

Donald Budenz, MD

Ophthalmology · Chapel Hill, NCNPI 1063455749

Payments from drug & device makers

$17,107in general payments, 2019–2025

Across 24 payments — averaging $712.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$9K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
  • Alcon$2K
  • Glaukos Corporation$2K
  • Alcon Research LLC$1K
  • NEW World Medical,inc.$707
  • plus $252 from 3 others

What the payments were for

  • Consulting fees$7,47544%
  • Speaking & faculty fees$8,84052%
  • Travel & lodging$1131%
  • Food & beverage$5403%
  • Education$1201%
  • Gifts$190%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,107 in reported general payments places this provider in the 85th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$65,205
Medicare patients
172
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate394$11,192
LumiganBimatoprost20$10,326
RhopressaNetarsudil Mesylate12$7,949
Brimonidine Tartrate73$3,778
Latanoprost312$3,569
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat158$2,695
Travoprost17$2,159
Ketorolac Tromethamine133$2,056
Ofloxacin183$1,963
Dorzolamide-TimololDorzolamide/Timolol/Pf13$1,281
Timolol Maleate67$697
Dorzolamide Hcl22$489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$120$10,32620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →